Evidence map›Paper›PMID 22442496›Full record

ReviewJournal of leukocyte biology2012

The multiple facets of thymic stromal lymphopoietin (TSLP) during allergic inflammation and beyond.

Florence Roan, Bryan D Bell, Thomas A Stoklasek, Masayuki Kitajima, Hongwei Han, Steven F Ziegler

Abstract readReview
In one paragraph

Review in Journal of leukocyte biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 91 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Severe Asthmatic Responses: The Impact of TSLP.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Florence RoanImmunology Program, Benaroya Research Institute, Seattle, WA, USA.
Bryan D Bell
Thomas A Stoklasek
Masayuki Kitajima
Hongwei Han
Steven F Ziegler
Benaroya Research InstituteUniversity of Washington · US

Funding

Thymic Stromal Lymphopoietin (TSLP) and Lung Inflammation and ImmP01HL098067 · NHLBI · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI FREVERT, CHARLES WAYNE · 2010 to 2014
$13.5M
TSLP and the Pathophysiology of AsthmaR01AI068731 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI ZIEGLER, STEVEN F · 2006 to 2016
$4.5M
Regulation of TSLP receptor expression and function in eczema in mice and manR01AR059058 · NIAMS · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A, ZIEGLER, STEVEN F · 2011 to 2015
$2.7M
TRAINING PEDIATRIC SCIENTISTS IN BASIC IMMUNOLOGYT32AI007411 · NIAID · UNIVERSITY OF WASHINGTON · PI GOVERMAN, JOAN M · 1993 to 2012
$2.6M
Regulation of TSLP-Mediated Skin InflammationR01AR055695 · NIAMS · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI CAMPBELL, DANIEL J, HAMERMAN, JESSICA A · 2009 to 2013
$2.0M
TSLP and Contact HypersensitivityR01AR056113 · NIAMS · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI ZIEGLER, STEVEN F · 2008 to 2012
$2.0M
Functional Biology of Intestinal Epithelial Cells in Food AllergyR21AI087990 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ARTIS, DAVID, ZIEGLER, STEVEN F · 2010 to 2011
$484k
TSLP and Childhood AsthmaR21HL102708 · NHLBI · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI ZIEGLER, STEVEN F · 2011 to 2012
$468k
NHLBI NIH HHS 1P01HL098067-02NHLBI NIH HHS 1R21HL102708-01A1NHLBI NIH HHS P01 HL098067NHLBI NIH HHS R21 HL102708NIAID NIH HHS 5R01AI068731-05NIAID NIH HHS 5R21AI087990-02NIAID NIH HHS 5T32AI007411-19NIAID NIH HHS R01 AI068731NIAID NIH HHS R21 AI087990NIAID NIH HHS T32 AI007411NIAMS NIH HHS 1R01AR059058-01A1NIAMS NIH HHS 5R01AR055695-03NIAMS NIH HHS 5R01AR056113-04NIAMS NIH HHS R01 AR055695NIAMS NIH HHS R01 AR056113NIAMS NIH HHS R01 AR059058
6 · The paper itself

Abstract

Originally shown to promote the growth and activation of B cells, TSLP is now known to have wide-ranging impacts on hematopoietic and nonhematopoietic cell lineages, including DCs, basophils, eosinophils, mast cells, CD4(+), CD8(+), and NK T cells, B cells, and epithelial cells. Whereas the role of TSLP in the promotion of TH2 responses has been studied extensively in the context of lung- and skin-specific allergic disorders, it is becoming increasingly clear that TSLP may impact multiple disease states within multiple organ systems, including the blockade of TH1/TH17 responses and the promotion of cancer and autoimmunity. This review will highlight recent advances in the understanding of TSLP signal transduction, as well as the role of TSLP in allergy, autoimmunity, and cancer. Importantly, these insights into the multifaceted roles of TSLP could potentially allow for novel, therapeutic manipulations of these disorders.

Indexed as

AnimalsAutoimmune DiseasesCytokinesDendritic CellsHumansHypersensitivityInflammationLeukocytesNeoplasmsSignal TransductionThymic Stromal LymphopoietinCytokinesThymic Stromal Lymphopoietin

Identifiers

PMID22442496
PMCPMC3360473
OpenAlexW2104676113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.